Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | STK39 | Q9UEW8 | 3/20 | 0.51 |
| ▸ | PNLIP | P16233 | 6/20 | 0.49 |
| ▸ | PYGL | P06737 | 4/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661386 | 0.80 | GCGR (0.87) | GCGRRAB9ANPC1STK39PNLIP | |
| SCHEMBL11036755 | 0.79 | RAB9A (0.60) | GCGRMEN1RAB9AKMT2ANPC1 | |
| SCHEMBL8660806 | 0.77 | GCGR (0.61) | GCGRMEN1RAB9AKMT2ANPC1 | |
| SCHEMBL10746567 | 0.77 | PYGL (0.64) | GCGRRAB9ANPC1STK39PNLIP | |
| SCHEMBL641133 | 0.75 | HPGD (0.62) | CHRM1MAPT | |
| SCHEMBL8660867 | 0.74 | PNLIP (0.53) | GCGRMEN1RAB9AKMT2ANPC1 | |
| SCHEMBL4150117 | 0.74 | CHRM1 (0.57) | MEN1KMT2ASTK39CHRM1MAPT | |
| SCHEMBL8657550 | 0.73 | GCGR (0.57) | GCGRMEN1RAB9AKMT2ANPC1 | |
| SCHEMBL8657049 | 0.73 | GCGR (0.59) | GCGRMEN1RAB9AKMT2ANPC1 | |
| SCHEMBL11388824 | 0.73 | GCGR (0.62) | GCGRMEN1RAB9AKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902144-B2 | Carrier-molecule-affinitive substance which has an association constant KA relative to a carrier molecule greater than 103 M-1 via a noncovalent bond | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20030185793-A1 | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same | Vergell Medical S.A. (CH) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185793-A1 | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same | SLCO1B1, SLCO1B3, SLCO1A2 | GCGR 1213/4885MEN1 1538/4885RAB9A 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.